Notification That Quarterly Report Will Be Submitted Late (nt 10-q)
August 18 2020 - 6:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
|
FORM
12b-25
|
SEC
FILE NUMBER
000-52218
|
|
NOTIFICATION
OF LATE FILING
|
CUSIP
NUMBER
68235A101
|
(Check
one):
|
[ ] Form 10-K [ ] Form 20-F [ ] Form 11-K [X] Form 10-Q [ ] Form 10-D [ ] Form N-SAR
[ ] Form N-CSR
|
|
|
|
For
Period Ended: June 30, 2020
|
|
|
|
[ ]
Transition Report on Form 10-K
|
|
|
|
[ ]
Transition Report on Form 20-F
|
|
|
|
[ ]
Transition Report on Form 11-K
|
|
|
|
[ ]
Transition Report on Form 10-Q
|
|
|
|
[ ]
Transition Report on Form N-SAR
|
|
|
|
For
the Transition Period Ended: _____________
|
Nothing
in this form shall be construed to imply that the Commission
has
verified any information contained herein.
If
the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART
I — REGISTRANT INFORMATION
OncBioMune
Pharmaceuticals, Inc.
Full
Name of Registrant
Former
Name if Applicable
15000
W. 6th Ave., #400
Address
of Principal Executive Office (Street and Number)
Golden,
CO 80401
City,
State and Zip Code
PART
II — RULES 12b-25(b) AND (c)
If
the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule
12b-25(b), the following should be completed. (Check box if appropriate)
|
(a)
|
The
reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
|
|
|
|
[X]
|
(b)
|
The
subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, 11-K, Form N-SAR, or N-CSR, or portion
thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly
report of transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on
or before the fifth calendar day following the prescribed date; and
|
|
|
|
|
(c)
|
The
accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.
|
PART
III — NARRATIVE
State
below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report portion
thereof, could not be filed within the prescribed time period.
OncBioMune
Pharmaceuticals, Inc. (the “Company”) is unable to file its Quarterly Report on Form 10-Q for the quarter ended June
30, 2020 (the “Form 10-Q”) within the prescribed time period without unreasonable effort or expense for the reasons
set forth below. The Company does expect that the Quarterly Report will be filed on or before the fifth calendar day following
the prescribed due date.
As
previously disclosed, on June 5, 2020, the Company completed its previously announced acquisition of substantially all of the
assets of Avant Diagnostics, Inc. (“Avant”) and the simultaneous conversion of the Company’s outstanding convertible
notes, promissory notes and other debts into preferred equity. The
Company acquired the assets of Avant in exchange for Series D-1 Convertible Preferred Stock of the Company which are convertible
into 54.55% of the outstanding equity of the Company on a fully-diluted basis. For accounting purposes, the acquisition
is treated as a “reverse acquisition” under accounting principles generally accepted in the United States and Avant
is considered the accounting acquirer. Accordingly, Avant’s historical results of operations will replace the Company’s
historical results of operations for all periods prior to the merger and, for all periods following the merger, the results of
operations of the combined company will be included in the registrant’s financial statements. Due
to the timing of the completion of the Transaction, the complexity of accounting for the Transaction, the size of the Transaction
relative to its existing operations and additional effort expended related to subsequent consolidation activities, the Company
requires additional time to prepare the financial statements and the accompanying notes disclosed in the Quarterly Report.
PART
IV — OTHER INFORMATION
(1)
|
Name
and telephone number of person to contact in regard to this notification
|
|
Andrew
Kucharchuk
|
|
888
|
|
585-4923
|
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
(2)
|
Have
all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the
Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required
to file such report(s) been filed? If answer is no, identify report(s).
|
|
|
|
Yes
[X] No [ ]
|
|
|
(3)
|
Is
it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year
will be reflected by the earnings statements to be included in the subject report or portion thereof?
|
|
|
|
Yes
[X] No [ ]
|
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
|
|
|
|
On
June 5, 2020, the Company acquired substantially all of the assets of Avant as described in Part III above. As a result, we
expect our results of operations to be significantly different from those previously presented. We are in the process of completing
the accounting for the acquisition and quantifying the differences.
|
OncBioMune
Pharmaceuticals, Inc.
(Name
of Registrant as Specified in Charter)
has
caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.
Date:
August 17, 2020
|
By:
|
/s/
Andrew Kucharchuk
|
|
Name:
|
Andrew
Kucharchuk
|
|
Title:
|
Acting
Chief Financial Officer
|
INSTRUCTION:
The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and
title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of
the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority
to sign on behalf of the registrant shall be filed with the form.
ATTENTION
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001)